BiotechTube

Venetoclax + Dexamethasone + Daratumumab

Phase 1/2Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AL Amyloidosis

Conditions

AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease

Trial Timeline

Jan 8, 2024 → Dec 31, 2028

NCT ID
NCT05486481

About Venetoclax + Dexamethasone + Daratumumab

Venetoclax + Dexamethasone + Daratumumab is a phase 1/2 stage product being developed by AbbVie for AL Amyloidosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05486481. Target conditions include AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease.

What happened to similar drugs?

0 of 12 similar drugs in AL Amyloidosis were approved

Approved (0) Terminated (2) Active (10)
🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05486481Phase 1/2Withdrawn

Competing Products

20 competing products in AL Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
22
VELCADEJohnson & JohnsonPhase 1/2
32
ABBV-383 (Etentamig)AbbViePhase 1/2
39
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
33
Carfilzomib + DexamethasoneAmgenPhase 1
29
IdelalisibGilead SciencesPhase 2
27
TafamidisPfizerPre-clinical
26
TafamidisPfizerPre-clinical
30
Fx-1006APfizerPhase 2
35
tafamidisPfizerPre-clinical
26
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
31
IsatuximabBristol Myers SquibbPhase 2
42
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
33
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
27
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
38
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
44
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
PatisiranAlnylam PharmaceuticalsPhase 3
37